Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Open access

Abstract

PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1,2, who were germline BRCA1 and BRCA2 wild type 3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-07384-2

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Trial CONSORT diagram. *The first main reason for treatment discontinuation was reported.
Fig. 1 Trial CONSORT diagram. *The first main reason for treatment discontinuation was reported.CC BY · PubMed Central
Fig. 2 pCR rate by treatment arm and TIL group. a,b, pCR rate by treatment arm (a) and TIL group (≥60% versus <60%) (b). Data were analysed from a total of 276 patients in the research (gap schedule) and 267 control arms. Error bars, 95% CI of the proportion based on exact method. The statistical test was based on the two-tailed chi-squared test.
Fig. 2 pCR rate by treatment arm and TIL group. a,b, pCR rate by treatment arm (a) and TIL group (≥60% versus <60%) (b). Data were analysed from a total of 276 patients in the research (gap schedule) and 267 control arms. Error bars, 95% CI of the proportion based on exact method. The statistical test was based on the two-tailed chi-squared test.CC BY · PubMed Central
Fig. 3 Kaplan–Meier curves of key survival end points. a–c, EFS (a), OS (b) and DDFS (c) in patients in the modified intention-to-treat group by treatment arm.
Fig. 3 Kaplan–Meier curves of key survival end points. a–c, EFS (a), OS (b) and DDFS (c) in patients in the modified intention-to-treat group by treatment arm.CC BY · PubMed Central
Fig. 4 Kaplan–Meier curves of survival by pathological response and treatment arm. a,b, EFS by pathological response (a) and by pathological response and treatment arm (b). c,d, OS by pathological response (c) and by pathological response and treatment arm (d) in patients in the modified intention-to-treat group.
Fig. 4 Kaplan–Meier curves of survival by pathological response and treatment arm. a,b, EFS by pathological response (a) and by pathological response and treatment arm (b). c,d, OS by pathological response (c) and by pathological response and treatment arm (d) in patients in the modified intention-to-treat group.CC BY · PubMed Central
Extended Data Fig. 1 Trial Flow Chart: PARTNER Trial for the TNBC Cohort. Trial Flow Chart: PARTNER Trial for the TNBC Cohort.
Extended Data Fig. 1 Trial Flow Chart: PARTNER Trial for the TNBC Cohort. Trial Flow Chart: PARTNER Trial for the TNBC Cohort.CC BY · PubMed Central
Extended Data Fig. 2 Forest plot of the primary end-point in subgroups. The data are the numbers and proportions of patients with pathological complete response (pCR). Data were analysed from a total of 276 in research (gap schedule) and 267 control arms. Estimates are the difference in the pCR and 95% CI based on the score method between research arm and control arm.
Extended Data Fig. 2 Forest plot of the primary end-point in subgroups. The data are the numbers and proportions of patients with pathological complete response (pCR). Data were analysed from a total of 276 in research (gap schedule) and 267 control arms. Estimates are the difference in the pCR and 95% CI based on the score method between research arm and control arm.CC BY · PubMed Central
Extended Data Fig. 3 Additional Kaplan-Meier curves of survival endpoints (part 1). Relapse free survival (A), local recurrence free survival (B), time-to-second cancer (C) and breast cancer specific survival (D) by treatment arm (control and research arm).
Extended Data Fig. 3 Additional Kaplan-Meier curves of survival endpoints (part 1). Relapse free survival (A), local recurrence free survival (B), time-to-second cancer (C) and breast cancer specific survival (D) by treatment arm (control and research arm).CC BY · PubMed Central
Extended Data Fig. 4 Additional Kaplan-Meier curves of survival endpoints (part 2). Relapse free survival (A), overall survival (B), and distant disease-free survival (C) by treatment arm (control, research arm, and dropped arm) in all patients.
Extended Data Fig. 4 Additional Kaplan-Meier curves of survival endpoints (part 2). Relapse free survival (A), overall survival (B), and distant disease-free survival (C) by treatment arm (control, research arm, and dropped arm) in all patients.CC BY · PubMed Central
Extended Data Fig. 5 Additional Kaplan-Meier curves of survival endpoints (part 3). Relapse free survival (A), overall survival (B), and distant disease-free survival (C) by treatment arm [control, research arm (gap-scheduled), and dropped arm (non-gap-scheduled)) in patients who were assessed at stage II.
Extended Data Fig. 5 Additional Kaplan-Meier curves of survival endpoints (part 3). Relapse free survival (A), overall survival (B), and distant disease-free survival (C) by treatment arm [control, research arm (gap-scheduled), and dropped arm (non-gap-scheduled)) in patients who were assessed at stage II.CC BY · PubMed Central
Extended Data Fig. 6 EQ-5D-5L visual analogue scale (VAS) scores and FACT-B total scores. Least-squares mean change from baseline of EQ-5D-5L visual analogue scale (VAS) score (A), FACT-B total score (B) and FACT-B subscales with trial outcome index and FACT-B total score at 4 months and 6 months. Asterisk indicates a statistical difference between the treatment arms of p < 0.05 based on two-tailed t-test with Tukey’s adjustment for multiple comparisons. Error bars, 95% CI of the estimated change score.
Extended Data Fig. 6 EQ-5D-5L visual analogue scale (VAS) scores and FACT-B total scores. Least-squares mean change from baseline of EQ-5D-5L visual analogue scale (VAS) score (A), FACT-B total score (B) and FACT-B subscales with trial outcome index and FACT-B total score at 4 months and 6 months. Asterisk indicates a statistical difference between the treatment arms of p < 0.05 based on two-tailed t-test with Tukey’s adjustment for multiple comparisons. Error bars, 95% CI of the estimated change score.CC BY · PubMed Central
Extended Data Fig. 7 Central pathology review Case Report Form. Central pathology review Case Report Form.
Extended Data Fig. 7 Central pathology review Case Report Form. Central pathology review Case Report Form.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 62

Metadata

Authors
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J. P., Sutherland, S., Staples, E., Scott, L. C., Davies, M., Palmer, C. A., Moody, M., Churn, M. J., Newby, J. C., Mukesh, M. B., Chakrabarti, A., Roylance, R. R., Schouten, P. C., Levitt, N. C., McAdam, K., Armstrong, A. C., Copson, E. R., McMurtry, E., Tischkowitz, M., Provenzano, E., & Earl, H. M.
Affiliations
  • University of Cambridge (GB)
  • Athens University of Economics and Business (GR)
  • Royal Devon University Healthcare NHS Foundation Trust (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Nottingham University Hospitals NHS Trust (GB)
  • Royal Bournemouth Hospital (GB)
  • Russells Hall Hospital (GB)
  • East Suffolk and North Essex NHS Foundation Trust (GB)
  • University Hospitals of Derby and Burton NHS Foundation Trust (GB)
  • Bedford Hospital NHS Trust (GB)
  • Pinderfields Hospital (GB)
  • Royal Hampshire County Hospital (GB)
  • Velindre Cancer Centre (GB)
  • University Hospitals Bristol and Weston NHS Foundation Trust (GB)
  • Mount Vernon Hospital (GB)
  • Barking, Havering And Redbridge University Hospitals NHS Trust (GB)
  • Beatson West of Scotland Cancer Centre (GB)
  • Swansea Bay University Health Board (GB)
  • Hinchingbrooke Hospital (GB)
  • West Suffolk NHS Foundation Trust (GB)
  • Worcestershire Acute Hospitals NHS Trust (GB)
  • Royal Free London NHS Foundation Trust (GB)
  • Poole Hospital (GB)
  • University College London Hospitals NHS Foundation Trust (GB)
  • Oxford University Hospitals NHS Trust (GB)
  • Peterborough City Hospital (GB)
  • The Christie NHS Foundation Trust (GB)
  • University of Southampton (GB)
Corresponding author
Abraham, Jean E.
Venue
Nature
Published
2024-04-08
Volume
629
Issue
8014
Pages
1142-1148
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4394580299
Cited by
53
References
36
Citations by year
2026: 20 · 2025: 22 · 2024: 11
FWCI
9.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
olaparib, triple-negative breast cancer, neoadjuvant therapy, PARP inhibitors, carboplatin, paclitaxel, anthracycline chemotherapy, pathological complete response, event-free survival, overall survival
MeSH terms
Progression-Free Survival, Pathologic Complete Response, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Phthalazines, Piperazines, Prospective Studies, Time Factors, Survival Analysis, Carboplatin, Paclitaxel, Germ-Line Mutation, Anthracyclines, BRCA1 Protein, Genes, BRCA1, Neoadjuvant Therapy, Genes, BRCA2, BRCA2 Protein, Young Adult, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. https://app.cochat.ai/papers/10.1038/s41586-024-07384-2
The paper
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., . . . Earl, H. M. (2024). The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. https://doi.org/10.1038/s41586-024-07384-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.